Entera Bio (ENTX) Expected to Announce Earnings on Friday

Entera Bio (NASDAQ:ENTX) is expected to be issuing its Q1 2026 results after the market closes on Friday, May 8th. Analysts expect the company to announce earnings of ($0.08) per share for the quarter. Individuals are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 14, 2026 at 4:00 PM ET.

Entera Bio (NASDAQ:ENTX) last announced its earnings results on Friday, March 27th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.02. On average, analysts expect Entera Bio to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Entera Bio Stock Up 4.5%

Entera Bio stock opened at $1.16 on Wednesday. The company has a 50 day moving average of $1.24 and a 200-day moving average of $1.74. Entera Bio has a twelve month low of $0.91 and a twelve month high of $3.22. The stock has a market capitalization of $54.08 million, a PE ratio of -4.46 and a beta of 1.54.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on ENTX shares. HC Wainwright reduced their target price on shares of Entera Bio from $10.00 to $9.00 and set a “buy” rating for the company in a research note on Monday, April 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Entera Bio in a research note on Tuesday, April 21st. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Entera Bio has an average rating of “Hold” and an average price target of $9.00.

Insider Buying and Selling at Entera Bio

In other Entera Bio news, Director Geno J. Germano acquired 20,000 shares of the stock in a transaction dated Monday, March 9th. The shares were bought at an average cost of $1.30 per share, for a total transaction of $26,000.00. Following the completion of the acquisition, the director directly owned 40,000 shares of the company’s stock, valued at approximately $52,000. This trade represents a 100.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last three months, insiders have purchased 58,000 shares of company stock worth $72,620. 10.38% of the stock is owned by company insiders.

Institutional Investors Weigh In On Entera Bio

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Superstring Capital Management LP acquired a new position in shares of Entera Bio during the 4th quarter worth about $33,000. Citadel Advisors LLC increased its position in shares of Entera Bio by 243.0% in the third quarter. Citadel Advisors LLC now owns 39,978 shares of the company’s stock valued at $77,000 after acquiring an additional 28,322 shares during the last quarter. HighTower Advisors LLC increased its position in shares of Entera Bio by 137.8% in the fourth quarter. HighTower Advisors LLC now owns 43,140 shares of the company’s stock valued at $84,000 after acquiring an additional 25,000 shares during the last quarter. Jane Street Group LLC raised its holdings in Entera Bio by 142.6% during the fourth quarter. Jane Street Group LLC now owns 74,064 shares of the company’s stock worth $144,000 after acquiring an additional 43,536 shares in the last quarter. Finally, Renaissance Technologies LLC raised its holdings in Entera Bio by 22.2% during the fourth quarter. Renaissance Technologies LLC now owns 108,001 shares of the company’s stock worth $210,000 after acquiring an additional 19,601 shares in the last quarter. 14.11% of the stock is currently owned by institutional investors and hedge funds.

Entera Bio Company Profile

Entera Bio, Inc is a clinical‐stage biopharmaceutical company pioneering the development of orally delivered peptide therapeutics. Utilizing its proprietary oral delivery platform, Entera Bio seeks to overcome the challenges of gastrointestinal absorption for large peptide molecules. The technology is designed to facilitate transit across the intestinal epithelium while preserving peptide structure and bioactivity, offering the potential for daily oral dosing in lieu of injectable formulations.

The company’s lead candidate, EB613, is an oral parathyroid hormone (PTH) analog under investigation for the treatment of osteoporosis.